Wells Fargo upgrades Editas to Overweight, lifts target to $6

 

 after Australian clearance for first-in-human EDIT-401 trial

• Australian regulatory and ethics approvals enable Phase 1/2 Strive trial of in vivo gene-editing therapy EDIT-401 to proceed.
• Strive Phase 1/2 study of EDIT-401 will enroll patients with heterozygous familial hypercholesterolemia for in vivo gene-editing treatment.
• Patient dosing with EDIT-401 is expected to begin this year following Australian regulatory and ethics approvals.
• Initial safety data from the Strive trial are anticipated in the first quarter of 2027.

https://finviz.com/stock?t=EDIT&p=d